Also known as atai Life Sciences, Beckley Psytech, and Atai Beckley N.V..
Adds clinical-stage neuroplastogens, including lead program BPL-003 for treatment‑resistant depression; transaction approved by AtaiBeckley shareholders.
Revenue rose 48% to $23.0bn driven by Mounjaro and Zepbound; updated 2026 revenue guidance to $85–87bn; retatrutide Phase 3 package complete supporting a Q1 2027 BLA.
